Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.

The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.

Methods for detecting angiopoietin-2 (Angpt-2) and/or thrombospondin-2 (Tsp-2) in a sample involve obtaining or having obtained a blood or plasma sample from a subject; and detecting Angpt-2 and Tsp-2 in the sample. Detecting can involve performing an assay to determine whether the sample includes Angpt-2 and/or Tsp-2 or elevated levels of Angpt-2 and/or Tsp-2. Elevated levels are indicative of acute heart failure.

A metasurface device includes a dielectric layer, an aluminum nanodisk and an aluminum layer. The dielectric layer includes top and bottom surfaces that are opposite each other. The dielectric layer also includes at least one ring-like cavity that extends between the top and bottom surfaces of the dielectric layer. The aluminum nanodisk is formed in the at least one ring-like cavity in the dielectric layer. The aluminum layer is formed on the dielectric layer and includes at least one ring-like cavity that extends between top and bottom surfaces of the aluminum layer. Each ring-like cavity in the aluminum layer corresponds to a ring-like cavity in the dielectric layer. Two or more analytes may emit fluorescence in response to light of a predetermined wavelength being incident on the metasurface device and in which the two or more analytes are present at the dielectric layer.

The present invention relates to a method for assessing the risk of stroke in a subject, said method comprising the steps of determining the amount of CES-2 in a sample from the subject, and comparing the amount of CES-2 to a reference amount, whereby the risk of stroke is to be assessed. Moreover, the present invention relates to a method for assessing the efficacy of an anticoagulation therapy and a method for identifying a subject being eligible to the administration of at least one anticoagulation medicament or being eligible for increasing the dosage of at least one anticoagulation medicament.

The present invention relates to a method of assessing the wound healing potency of a mesenchymal stem cell population. In addition, the present invention concerns a method of selecting a mesenchymal stem cell population for producing a stem cell population under cGMP conditions and a method of selecting a mesenchymal stem cell population for producing a stem cell population for subsequent pharmaceutical administration. Further, the present invention relates to a method of selecting a mesenchymal stem cell population for generating a master cell bank and to a method of identifying a tissue suitable as starting material for producing a mesenchymal stem cell population for pharmaceutical use.

An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor through Ang2, and methods of using the same.

The present invention relates generally to the field of medical diagnostics, and more particularly to a method for determining a vascular endothelial growth factor-A (VEGF) isoform concentration pattern of a biological sample. A biological material is obtained from a premature infant. A VEGF isoform concentration pattern of the biological material is determined using at least a first cytokine and a second cytokine. The VEGF isoform pattern is compared to a reference VEGF isoform concentration pattern that conveys a baseline concentration of at least a first cytokine and a second cytokine. A normal VEGF isoform concentration pattern is determined when the VEGF isoform concentration pattern is within a threshold percentage of the reference VEGF isoform concentration pattern. The VEGF isoform concentration pattern conveys concentration levels of at least the first cytokine and the second cytokine. The biological material may be a blood or a fecal sample obtained from a premature infant.

The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of SPON-1 in a sample from the subject, and comparing the amount of SPON-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of SPON-1.

The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.